Objective and design: The aim of this study is to investigate the inflammatory alterations due to the use of smokeless tobacco and dual use of smokeless tobacco and cigarettes, relative to smoking. Subjects: Plasma and saliva samples were collected from healthy smokers (SMK-100 subjects), moist snuff users (MSC-89 subjects), the dual users (DUSMK-49 subjects), and non-tobacco consumers (NTC-99 subjects) from two cross-sectional studies. Methods: Luminex Human InflammationMAP® 1.0 panel, a multiplex immunoassay. Results: SMK and DUSMK exhibited larger number of alterations in the expression of inflammatory analytes compared to NTC. Eight analytes were significantly elevated (p ≤ .05) within plasma samples of SMK compared to NTC, while one 1 analyte was elevated between the MSC and NTC groups. DUSMK exhibited different levels of 11 analytes, relative to NTC.
Introduction
Cigarette smoke is a complex aerosol that consists of over 8000 chemicals [1] , including 93 harmful and potentially harmful constituents as designated by the FDA [2] . Smoking has been causally related to several diseases, primarily those affecting the pulmonary and cardiovascular systems including cancer, coronary heart disease, and chronic obstructive pulmonary disease (COPD) [3] . The effects of cigarette smoking on human health have been extensively investigated at the organ, cellular, and molecular levels. Mechanistically, cigarette smoking has been linked to perturbations in many molecular pathways, including oxidative stress and immune response [4] . Oxidative moieties generated during cigarette combustion lead to lipid and DNA damage, and to the activation of lung epithelial cells and macrophages [5, 6] .
Activation of immune cells leads to secretion of inflammatory mediators, promotion of systemic inflammation, and elevation in the number of circulating leukocytes in chronic smokers [4] . Changes in the levels of inflammatory mediators, including the cytokines TNF-α and IL-6, and acute-phase proteins (APPs) such as C-reactive protein (CRP) and fibrinogen, have been documented in cigarette smokers [4] . These and other inflammatory markers have been identified as potential biomarkers of tobacco effect (BioEff) [7] [8] [9] [10] .
While cigarette smoking remains as the most common form of tobacco use in the United States, smokeless tobacco products (STPs), such as moist snuff and snus, are also marketed [11] . In contrast to cigarette smoking, oral STPs do not generate toxicants associated with the combustion process and are associated with reduced risk of adverse health effects compared to smoking [12] . It is now well recognized that a risk continuum is associated with different tobacco product classes. While combustible cigarette smoking is the most harmful and the nonuse of any tobacco is the least harmful option, STPs are associated with significantly reduced risk relative to cigarettes and non-combustible tobacco products may present less risk than cigarette smoking [13, 14] . Epidemiological data from USA and Sweden indicate that the consumption of moist snuff and snus is associated with reduced risk of cancer, COPD, and cardiovascular diseases [15] [16] [17] [18] [19] . Additionally, cross-sectional studies have demonstrated that across several biological pathways, STP users generally experience fewer perturbations than smokers, notwithstanding higher exposure to nicotine and tobacco specific nitrosamines [9] . These and other studies have led to the identification of several potential BioEff, which could aid in predicting the health effects associated with the use of different tobacco product classes [10, 20] .
Studies on the dual use of cigarettes and smokeless tobacco products are limited, and it is unclear where dual users fall on the risk continuum of tobacco use. It has been suggested that dual use may result in a reduction in smoking-related harm due to generally reduced cigarette consumption with dual users [21, 22] . With over 10% of adults in the United States using multiple tobacco products [23] , more studies on the health risks and systemic effects associated with the consumption of multiple tobacco products are necessary.
Since cigarette smoking induces a state of chronic inflammation, we investigated inflammatory protein profiles in plasma and saliva samples from smokers (SMK), STP users (moist snuff consumers [MSC]), dualusers of combustible cigarettes and moist snuff (DUSMK), and non-tobacco consumers (NTC) recruited into two cross-sectional studies. The Human InflammationMAP® 1.0 panel consisted of a large number of inflammatory proteins, which have been reported to be altered in smokers. Hence, this panel was chosen for investigating inflammation changes in smokers and STP users. The inflammatory profile data was compared among the different groups of tobacco consumers and NTC. This data will help in understanding the effects of these tobacco products on the inflammatory/immune responses and assist in understanding the comparative risks between combustible cigarettes and non-combustible tobacco products. Our results indicate that inflammatory cytokine levels are higher among combustible tobacco consumers relative to STP users and NTC, and five analytes emerged as potential BioEff.
Materials and methods

Study design
The clinical conduct of the two studies presented herein was approved by Independent Investigational Review Board, Inc. (currently Schulman Associates IRB, Inc., Fort Lauderdale, FL). Study and subject materials (inclusive of protocol, informed consent forms, recruitment materials, subject instructions) were IRB reviewed and approved; the first study on 18 March 2010 and the second study on 03 November 2009. Both studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice [24] and the Declaration of Helsinki [25] . In both studies, written informed consent was obtained from subjects prior to any study procedures being performed. Subjects were free to withdraw from the study for any reason and at any time, and were compensated for their time and travel.
The first study, termed "Biomarker Discovery Study," with Clinical Trials Registry identifier number NCT01923402, was a single-site, cross sectional study of male tobacco-product consumers and a male nontobacco-consuming control group, and was previously described [9, 10] . Briefly, a total of 120 generally healthy male subjects, aged 35-60 years were enrolled into one of three groups (40 subjects per group completed the study): exclusive long-term SMK, exclusive MSC, and NTC.
The second study was a multi-site, cross sectional study of regular users of different types of tobacco products. In this study, there were three groups that were consistent with the tobacco user groups in the first study. Those groups and a fourth group of DUSMK are presented herein. This multi-site study enrolled 220 male and female subjects aged 19-73 years into the following groups: SMK MSC, DUSMK, and NTC (Supplementary Table 1 ). A total of 217 subjects across the four cohorts completed the study: SMK = 60, MSC = 49, DUSMK = 49, and NTC = 59. The objectives and the design of this multi-site study were described previously at a scientific conference. 1 For both studies plasma and un-stimulated saliva samples were collected at clinical research units and shipped to a central laboratory per the study protocols. Samples were collected from the study subjects who fasted overnight from food (all groups) and tobacco (all tobacco consumer groups). The samples were shipped to Rules-Based Medicine (RBM, now Myriad RBM; Austin, TX) for cytokine profile measurements.
Cytokine profiling
Myriad RBM performed cytokine profile measurements using the Human InflammationMAP® 1.0 panel from Luminex Corporation. Briefly, this multiplex microsphere-based assay allows for the interrogation of 45 analytes simultaneously in a capture-sandwich format. In this assay, 5 μL of diluted capture-antibody microspheres with 5 μL blocker and 10 μL of either standard, pre-diluted sample, or control were incubated at room temperature in a hard-bottom microtiter plate for 1 h. Following incubation, 10 μL of biotinylated detection antibody was added to each well, mixed thoroughly and incubated for 1 h. The reaction contents were added to a pre-wet filter-membrane microtiter plate, the supernatant was aspirated, and the contents were washed twice with 100 μL wash buffer. After the final wash, the beads were suspended in 100 μL of wash buffer and the plate was analyzed on the Luminex platform.
Statistical analysis
Results for the plasma and saliva measures were sent from Myriad RBM to SciWit Inc. (Boulder, CO) for data analysis. For analytes where the reported value fell below the lower assay limit of quantitation (LLOQ) as defined by Myriad RBM, the entry was recorded as "LOW." For analytes where <50% of the entries were LOW, the LLOQ for that analyte was divided by 2 and this value replaced the "LOW" entry for the analyte. Analytes where ≥50% of the entries were LOW, were removed from further analysis. Mean and standard deviations of the analytes were calculated for each group and comparisons between cohort groups were completed using data transformed via the column range method. For this method, the transformed final value equals the original value minus the analyte minimum value divided by the analyte range, yielding a value between 0 and 1 for each analyte. Analysis of variance (ANOVA) using the un-pooled variance method was carried out to compare each of the groups to each other using the transformed data. All of the analytes identified at the p < .05 level of significance are described herein.
Results
Smokers exhibit markedly higher inflammatory protein expression compared to non-tobacco consumers
The general status of inflammation was assessed in tobacco consumers by profiling the levels of 45 inflammatory analytes in plasma and saliva samples collected from two cross-sectional studies conducted by R.J. Reynolds Tobacco Company (RJRT). A comparison of plasma inflammatory profiles of generally healthy SMK with NTC revealed significantly higher levels of 12 inflammation biomarkers in the plasma of tobacco smokers (Table 1) 
Moist snuff consumers exhibit reduced inflammatory Protein expression compared to smokers
A comparison of the inflammatory analytes between the plasma samples of SMK and MSC (Table 2 ) revealed 14 analytes were significantly higher in SMK (Table 2) . Of these, 7 analytes (alpha 1 antitrypsin [AAT], brain derived neurotrophic factor [BDNF], fibrinogen, haptoglobin, ICAM-1, T-cell-specific protein RANTES, and VEGF) were significantly higher within the plasma samples of SMK in both studies (Table 2) . A total of five analytes were significantly elevated in saliva samples from MSC and one analyte was higher in saliva samples from SMK compared to MSC; however, no analytes were consistently different between the two studies in saliva samples (Table 2) .
When comparing the results of MSC to NTC, only plasma FRTN levels were significantly higher in MSC than in NTC within both studies (Table 3) . Ferritin was the only analyte that was consistently different (higher in MSC) between MSC and NTC. Together, these results suggest that MSC and NTC have lower levels of most inflammatory markers compared to SMK.
DUSMK experience an altered inflammatory profile compared to moist snuff users and non-tobacco consumers
The inflammatory profile of DUSMK was evaluated to further [43] [44] [45] [46] [47] [48] [49] [50] [51] elucidate the role of combustible tobacco consumption in inflammation ( Table 4 ). The DUSMK cohort was not part of Study 1, and hence the results refer only to Study 2 for this cohort. DUSMK exhibited significantly elevated levels of 7 inflammatory analytes in plasma samples (BDNF, FRTN, ICAM-1, MMP-9, SCF, TIMP-1, and VEGF) when compared to NTC (Table 4) . TIMP-1 was also significantly increased in saliva samples compared to NTC (Table 4) . Compared to MSC, DUSMK exhibited higher levels of three inflammatory analytes (ICAM-1, MMP-9, and VEGF), while MSC had higher levels of MMP-2 and VCAM-1 (Table 4) in plasma samples; no analytes were significantly different in saliva samples. In comparing DUSMK and SMK, CRP and MMP-2 of plasma samples were increased in SMK, while monocyte chemotactic protein 1 (MCP-1) in saliva samples was higher in DUSMK (Table 4 ). These data suggest that smoking and consumption of moist snuff may alter the inflammatory proteins in different ways.
Potential biomarkers of tobacco use
The inflammatory profile of tobacco consumers was further evaluated to identify potential biomarkers distinguishing tobacco use. Although there were notable demographic differences between the two studies, five analytes (FRTN, ICAM-1, MMP-9 and VEGF and fibrinogen) emerged as potential biomarkers in plasma samples. MMP-9, ICAM-1, and VEGF were elevated (p < .02) in the plasma samples of both studies between SMK and NTC (Fig. 1A) . Fibrinogen, ICAM-1, and VEGF exhibited elevated levels (p < .02) within SMK of both studies when compared to MSC (Fig. 1B) . FRTN emerged as a biomarker distinguishing MSC and NTC (p < .02) within the two studies (Fig. 1C) . All of these markers, excluding fibrinogen, were also highly elevated (p ≤ .005) in DUSMK compared to NTC from the second study, further supporting the potential utility of these analytes as biomarkers of tobacco use.
Discussion
A key common objective of the two cross-sectional studies discussed in this manuscript was to evaluate how the use of different types of tobacco products modulates the inflammation process. We sought to identify potential BioEff in smokers, STP consumers, and dual users of moist snuff who also smoke. The results of this current work are: (1) our data from SMK groups is consistent with the published literature; (2) the MSC groups showed fewer perturbations in the inflammatory protein profiles compared to combustible tobacco consumers and were generally similar to NTC; (3) the SMK and DUSMK were more similar to each other, and exhibited inflammatory profiles distinct from NTC. This data suggests that use of combustible tobacco products drives inflammatory changes. Finally, our analysis also identified five potential biomarkers of effect: fibrinogen, ICAM-1, VEGF, MMP-9, and ferritin. These biomarkers could indicate an altered inflammatory state associated with smoking and may be useful in assessing tobacco products for regulatory purposes.
In this manuscript, we investigated the levels of inflammatory proteins from two independent cross-sectional studies that included smokers, moist snuff consumers and non-tobacco consumers. The subject demographics were, however, different. For example, the Study 1 included only males between ages 35-60, whereas the Study 2 included both males and females ranging from 19 to 73 years (Supplementary Table 1 ). Further, the results reported here were not normalized for cigarettes smoked per day, number of years of tobacco use, or other covariates. Notwithstanding the differences between the study cohorts, several consistent differences in the levels of inflammatory proteins were detected between the studies.
Of the 45 inflammatory analytes investigated, five emerged as potential biomarkers distinguishing tobacco use: Fibrinogen, ICAM-1, VEGF, MMP-9, and Ferritin. ICAM-1 is involved in cell adhesion and is expressed by vascular endothelial cells, epithelial cells, and cells of the immune system in response to inflammatory cytokines. Cigarette smoke has been shown to induce the expression of ICAM-1 on airway epithelial cells, and it has been suggested that increased expression of ICAM-1 could lead to the local accumulation of neutrophils [26, 27] . VEGF expression is mediated by inflammatory cytokines and can activate T-cells as well as induce proliferation and migration in endothelial cells. These functions of VEGF contribute to its role in carcinogenesis [28] . MMP-9 also plays a role in cell migration through the degradation of extracellular matrix components and is responsible for the activation and deactivation of cytokines and chemokines. Previous studies have identified elevated MMP-9 expression in smokers with emphysema, patients with COPD, and patients with asthma [29] . Fibrinogen is an important factor in the coagulation cascade and has been linked to cardiovascular disease [30] . Its role as a potential biomarker for Table 4 Inflammatory analytes significantly different between dual-users of combustible tobacco and moist snuff compared to non-tobacco consumers and single users of moist snuff and cigarettes. All analytes with p-value < 0.05 between SMK and MSC are presented. Shaded values indicate the highest mean analyte value.
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Cytokine 107 (2018) [43] [44] [45] [46] [47] [48] [49] [50] [51] tobacco effect has also been suggested previously [4, 8] , and is a known ligand of ICAM-1 [31] . Ferritin is responsible for storing iron in cells. Ferritin in serum is indicative of inflammation and has been correlated with a variety of diseases including cancer, coronary artery disease, hypertension, and stroke [32] . The effects of smoking on the immune system are complex and often seemingly contradictory, acting in a pro-inflammatory manner and as an immunosuppressor [33] . Cigarette smoke constituents, particularly 
Cytokine 107 (2018) [43] [44] [45] [46] [47] [48] [49] [50] [51] reactive oxygen species (ROS) produced during the combustion process, damage airway epithelial cells directly and activate signaling cascades leading to the secretion of inflammatory mediators promoting chronic immune cell recruitment and inflammation [6] . Smoking leads to an increase in the number of macrophages and neutrophils to the airways but impairs the function of these cells such that phagocytosis is reduced. Additionally, natural killer (NK) cells have reduced cytotoxic activity and cytokine production following exposure to cigarette smoke [5] . Together the effects of cigarette smoke on the cells of the innate immune response lead to immune suppression [34] . Cigarette smoke also affects the adaptive immune response, including polarization of the T helper 2-type inflammatory response, the formation of B cell follicles in the lungs of long term smokers, and increased allergic sensitization and autoimmunity [5] . All told, the long term effects of cigarette smoking on inflammation are complex. The collective dysregulation of the immune response could contribute to several smoking-induced pathophysiological changes, including increased susceptibility of smokers to microbial infections and cancer. In a study comparing the risk of chronic inflammatory diseases associated with smoking and moist snuff use, it was determined that use of STP, unlike smoking, does not affect the risk of rheumatoid arthritis, ulcerative colitis, Crohn's disease, sarcoidosis, or multiple sclerosis [35] . In contrast to SMK who display elevated total white blood cell and neutrophil counts [33, 34] , MSC are similar to NTC in these parameters [9] . However, murine T cells exposed to STP extracts demonstrated altered cytokine secretion profiles consistent with a state of increased inflammation and sensitization [36] . STP also has been linked to inflammation of the buccal and gingival mucosa via activation of the complement system [37] , which is consistent with our findings of increased Complement C3 in MSC in saliva samples compared with NTC from the second study (Table 3) . However, this result is inconsistent between the two studies (Table 3) .
To our knowledge, this is the first report on the evaluation of the inflammatory profile of dual tobacco use (smokers and users of moist snuff). Dual cigarette/STP use has not been found to present health risks above those observed from cigarette smoking alone (21, 22) . While it is generally agreed that use of STPs presents significantly less risk of adverse health effects than smoking (13, 26) , less is known about the specific effects of dual use of cigarettes and STP on the immune response. There have been limited investigations into potential biomarkers of dual tobacco use and its effects on inflammation. When cigarette smokers reduced cigarette consumption by 50-60% while using STPs, levels of toxicants were reduced after five days [20, 38] . The findings from the DUSMK and SMK suggest that smoking exerts marked influence on inflammation, although additional research is required to fully understand the correlation between identified biomarkers and the alterations in immune/inflammatory responses.
BioEff have been studied in the context of cardiovascular disease [39] [40] [41] [42] , cancer [43, 44] , as well as oxidative stress and inflammation [7] [8] [9] [10] . The identification of biomarkers of inflammation, which can distinguish different consumers of tobacco products, may provide insight into the mechanisms through which smoking leads to changes in the immune response. Our findings of altered expression of eight immune markers between SMK and NTC are consistent with the findings of Shiels et al. who reported a broad range of alterations in systemic immune and inflammation markers among long-term smokers [7] . However, while most of the inflammatory analytes were elevated among SMK compared to MSC and NTC in our study groups, Shiels et al. reported elevated levels of only three analytes, while seven markers were lower among long-term smokers. Interestingly, Shiels et al. described trends in the expression profiles of multiple analytes following smoking cessation, with levels of immune markers in former smokers approaching those of never smokers in a manner that corresponded with the time since quitting [7] . Recently, Selvarajah et al. also reported elevated cytokine expression as a consequence of smoking, as well as in patients with chronic obstructive pulmonary disease. The elevated levels of INF-γ, TGFβ, IL-8, and MCP-1 reported suggest generalized, systemic, low-grade inflammation [45] .
Results reported here from inflammation panel profiling showing elevated expression of ICAM-1 in SMK and DUSMK is also observed in other studies examining the inflammatory profiles of smokers [8, 46] , thus further supporting an altered state of inflammation due to smoking. Elevated levels of plasma fibrinogen in SMK compared to MSC (Table 2 ), but not between SMK and NTC (Table 1) , were observed. Independent assays that specifically determined fibrinogen levels in the same sample set showed that SMK have higher levels of fibrinogen compared to MSC [9] . Increased expression of blood fibrinogen levels in current smokers compared to never smokers has also been reported previously [47] .
Analysis of matching plasma and saliva samples collected from the biomarker study subjects (Study 1) revealed that SMK generally exhibited distinct biomarker patterns relative to MSC and NTC and that the biomarkers in MSC were similar to NTC, except for nicotine and its metabolites and tobacco-specific nitrosamines (TSNAs) [9] . For example, combustion-related biomarkers of exposure were significantly higher in SMK. Further, evaluation of several BioEff indicative of oxidative stress and inflammation were at comparable levels between MSC and NTC, whereas SMK exhibited perturbations in those pathways. Global metabolomic profiles of matching plasma, saliva and urine from the biomarker discovery study also suggested increased oxidative stress and inflammation in SMK, whereas MSC profiles largely resembled those of NTC [10] . Further, gene expression profiles from peripheral blood mononuclear cells of the same cohorts (biomarker discovery study) also revealed that MSC and NTC were more similar to each other, whereas SMK manifested a distinct gene expression pattern indicative of altered inflammation status, among others [48] .
We found that DUSMK exhibited altered analyte expression, similar to SMK, which may reflect the level of combustible tobacco consumption within this group. A study investigating the biomarkers of tobacco exposure in SMK who switched to dual use of cigarettes and snus revealed modest percent reductions in the levels of biomarkers of exposure following five days of dual use, compared to the substantial reductions seen when subjects switched from cigarettes to no tobacco use (100% reduction) or STP [20] . This was despite a reduction in smoking frequency by approximately 60% in the DUSMK group. Interestingly, it has been reported that even a low threshold of cigarette consumption (1-10 cigarettes per day) is sufficient to alter systemic levels of immune/inflammation markers in smokers [7] .
In summary, we examined the inflammatory profile of SMK, DUSMK, MSC, and NTC within two clinical studies. Our results demonstrate SMK and DUSMK exhibit altered inflammatory profiles compared to NTC, while the inflammatory profile of MSC was more similar to that of NTC. These findings support a risk continuum for tobacco use, whereby users of STP are at reduced risk compared to combustible tobacco users [13] . The identification of five potential biomarkers of inflammation reported herein may be helpful in providing additional scientific basis for the relative risk continuum among tobacco product classes, and in further elucidating the molecular mechanisms of smoking-related-diseases. Our current work suggests the increased expression of inflammatory analytes observed within SMK and DUSMK is a result of combustible tobacco consumption. Furthermore, fibrinogen, ICAM-1, VEGF, MMP-9, and ferritin may serve as BioEff and could be useful in differentiating the effects of exposure to different classes of tobacco products.
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